

Jeffrey Browning

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1997126/publications.pdf>

Version: 2024-02-01

84
papers

17,036
citations

39113

52
h-index

71088

80
g-index

84
all docs

84
docs citations

84
times ranked

15912
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunofibroblasts regulate LT α 3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction. <i>Communications Biology</i> , 2022, 5, 413.	2.0	8
2	Lung-resident memory B cells protect against bacterial pneumonia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	62
3	Queen's Gambit: B Cell to Follicle. <i>Journal of Immunology</i> , 2021, 207, 753-754.	0.4	0
4	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 379-386.	0.5	97
5	Amelioration of Murine Autoimmune Pancreatitis by Targeted LT α 2R Inhibition and Anti-CD20 Treatment. <i>ImmunoHorizons</i> , 2020, 4, 688-700.	0.8	3
6	Extensive CD34-to-CD90 Fibroblast Transition Defines Regions of Cutaneous Reparative, Hypertrophic, and Keloidal Scarring. <i>American Journal of Dermatopathology</i> , 2019, 41, 16-28.	0.3	16
7	Perivascular Adventitial Fibroblast Specialization Accompanies T Cell Retention in the Inflamed Human Dermis. <i>Journal of Immunology</i> , 2019, 202, 56-68.	0.4	22
8	Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β 2 Receptor Fusion Protein, in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 1470-1480.	2.9	56
9	Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. <i>Scientific Reports</i> , 2017, 7, 41605.	1.6	61
10	Lymphotoxin β 2 receptor signalling executes <i>Helicobacter pylori</i> -driven gastric inflammation in a T4SS-dependent manner. <i>Cut</i> , 2017, 66, 1369-1381.	6.1	33
11	Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90. <i>American Journal of Pathology</i> , 2016, 186, 2650-2664.	1.9	48
12	The lymphotoxin β 2 receptor is a potential therapeutic target in renal inflammation. <i>Kidney International</i> , 2016, 89, 113-126.	2.6	16
13	Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis. <i>Journal of Clinical Investigation</i> , 2016, 126, 4331-4345.	3.9	38
14	Pristane-Accelerated Autoimmune Disease in (SWR X NZB) F1 Mice Leads to Prominent Tubulointerstitial Inflammation and Human Lupus Nephritis-Like Fibrosis. <i>PLoS ONE</i> , 2016, 11, e0164423.	1.1	7
15	A Longitudinal Biomarker for the Extent of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2015, 67, 3004-3015.	2.9	95
16	Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. <i>Nature Immunology</i> , 2015, 16, 1235-1244.	7.0	278
17	Lymphotoxin-LIGHT Pathway Regulates the Interferon Signature in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2014, 9, e112545.	1.1	40
18	Role of the Lymphotoxin/LIGHT System in the Development and Maintenance of Reticular Networks and Vasculature in Lymphoid Tissues. <i>Frontiers in Immunology</i> , 2014, 5, 47.	2.2	73

#	ARTICLE	IF	CITATIONS
19	Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. <i>Science</i> , 2014, 343, 1221-1228.	6.0	774
20	The Lymphotoxin Network: Orchestrating a Type I interferon response to optimize adaptive immunity. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 139-145.	3.2	29
21	Lymphotoxin β receptor mediates caspase-dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of NF- κ B activation. <i>Carcinogenesis</i> , 2013, 34, 1105-1114.	1.3	27
22	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. <i>Blood</i> , 2012, 119, 1570-1580.	0.6	221
23	Follicular Dendritic Cells Emerge from Ubiquitous Perivascular Precursors. <i>Cell</i> , 2012, 150, 194-206.	13.5	329
24	Lymphotoxin β Receptor Signaling Promotes Development of Autoimmune Pancreatitis. <i>Gastroenterology</i> , 2012, 143, 1361-1374.	0.6	45
25	Regulation of TH2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cells. <i>Nature Immunology</i> , 2012, 13, 681-690.	7.0	187
26	Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. <i>Journal of Clinical Investigation</i> , 2012, 122, 778-778.	3.9	1
27	Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2011, 13, R182.	1.6	71
28	JÃ¼rg Tschopp (1951-2011). <i>Immunity</i> , 2011, 34, 451-452.	6.6	0
29	LTBR-Pathway in Sjogren's Syndrome: CXCL13 Levels and B-cell-Enriched Ectopic Lymphoid Aggregates in NOD Mouse Lacrimal Glands Are Dependent on LTBR. <i>Advances in Experimental Medicine and Biology</i> , 2011, 691, 383-390.	0.8	11
30	Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. <i>Journal of Clinical Investigation</i> , 2011, 121, 3991-4002.	3.9	208
31	Workshop Summary: Control of Lymphocyte Function and Repertoire by the TNF Superfamily. <i>Advances in Experimental Medicine and Biology</i> , 2011, 691, 351-352.	0.8	0
32	TRAF3 Controls Activation of the Canonical and Alternative NF- κ B by the Lymphotoxin Beta Receptor. <i>Journal of Biological Chemistry</i> , 2010, 285, 12971-12978.	1.6	75
33	Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LT β R. <i>MAbs</i> , 2009, 1, 128-141.	2.6	106
34	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 295-308.	7.7	345
35	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 447.	7.7	1
36	Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren syndrome in salivary glands of non-obese diabetic mice. <i>Arthritis Research and Therapy</i> , 2009, 11, R24.	1.6	107

#	ARTICLE	IF	CITATIONS
37	Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. <i>Immunological Reviews</i> , 2008, 223, 202-220.	2.8	90
38	B cells move to centre stage: novel opportunities for autoimmune disease treatment. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 564-576.	21.5	239
39	Targeting the Lymphotoxin- $\hat{1}^2$ Receptor with Agonist Antibodies as a Potential Cancer Therapy. <i>Cancer Research</i> , 2006, 66, 9617-9624.	0.4	95
40	Lymphotoxin- $\hat{1}^2$ Receptor Signaling Is Required for the Homeostatic Control of HEV Differentiation and Function. <i>Immunity</i> , 2005, 23, 539-550.	6.6	233
41	TAJ/TROY, an Orphan TNF Receptor Family Member, Binds Nogo-66 Receptor 1 and Regulates Axonal Regeneration. <i>Neuron</i> , 2005, 45, 353-359.	3.8	363
42	Lymphotoxin/LIGHT, lymphoid microenvironments and autoimmune disease. <i>Nature Reviews Immunology</i> , 2003, 3, 642-655.	10.6	263
43	BAFFANDAPRIL: A Tutorial on B Cell Survival. <i>Annual Review of Immunology</i> , 2003, 21, 231-264.	9.5	874
44	A Role for the Lymphotoxin/LIGHT Axis in the Pathogenesis of Murine Collagen-Induced Arthritis. <i>Journal of Immunology</i> , 2003, 171, 115-126.	0.4	109
45	A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT. <i>Journal of Clinical Investigation</i> , 2003, 112, 755-767.	3.9	52
46	Visualization of Lymphotoxin- $\hat{1}^2$ and Lymphotoxin- $\hat{1}^2$ Receptor Expression in Mouse Embryos. <i>Journal of Immunology</i> , 2002, 168, 5079-5087.	0.4	80
47	BAFF: A fundamental survival factor for B cells. <i>Nature Reviews Immunology</i> , 2002, 2, 465-475.	10.6	619
48	Manipulation of lymphoid microenvironments in nonhuman primates by an inhibitor of the lymphotoxin pathway. <i>Journal of Clinical Investigation</i> , 2002, 110, 1359-1369.	3.9	51
49	Manipulation of lymphoid microenvironments in nonhuman primates by an inhibitor of the lymphotoxin pathway. <i>Journal of Clinical Investigation</i> , 2002, 110, 1359-1369.	3.9	23
50	Effect of mature lymphocytes and lymphotoxin on the development of the follicle-associated epithelium and M cells in mouse Peyer's patches. <i>Gastroenterology</i> , 2001, 120, 1173-1182.	0.6	90
51	BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF. <i>Science</i> , 2001, 293, 2108-2111.	6.0	827
52	Elimination of Colonic Patches with Lymphotoxin $\hat{1}^2$ Receptor-Ig Prevents Th2 Cell-Type Colitis. <i>Journal of Immunology</i> , 2001, 167, 2781-2790.	0.4	86
53	Essential Role of Lymph Nodes in Contact Hypersensitivity Revealed in Lymphotoxin- $\hat{1}^2$ Deficient Mice. <i>Journal of Experimental Medicine</i> , 2001, 193, 1227-1238.	4.2	54
54	A chemokine-driven positive feedback loop organizes lymphoid follicles. <i>Nature</i> , 2000, 406, 309-314.	13.7	1,103

#	ARTICLE	IF	CITATIONS
55	Functional Effects of TNF and Lymphotoxin $\hat{1}\hat{2}$ on FDC-like Cells. Cellular Immunology, 2000, 203, 134-143.	1.4	45
56	Baff Mediates Survival of Peripheral Immature B Lymphocytes. Journal of Experimental Medicine, 2000, 192, 1453-1466.	4.2	625
57	A Soluble Form of B Cell Maturation Antigen, a Receptor for the Tumor Necrosis Factor Family Member April, Inhibits Tumor Cell Growth. Journal of Experimental Medicine, 2000, 192, 1677-1684.	4.2	239
58	Baff Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population. Journal of Experimental Medicine, 2000, 192, 129-136.	4.2	360
59	Lymphotoxin $\hat{1}\hat{2}$ and Tumor Necrosis Factor Are Required for Stromal Cell Expression of Homing Chemokines in B and T Cell Areas of the Spleen. Journal of Experimental Medicine, 1999, 189, 403-412.	4.2	529
60	Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations. Journal of Experimental Medicine, 1999, 190, 1697-1710.	4.2	1,347
61	The Requirement of Membrane Lymphotoxin for the Presence of Dendritic Cells in Lymphoid Tissues. Journal of Experimental Medicine, 1999, 190, 629-638.	4.2	140
62	BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth. Journal of Experimental Medicine, 1999, 189, 1747-1756.	4.2	1,213
63	Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway. Nature Medicine, 1999, 5, 1370-1374.	15.2	60
64	A role for lymphotoxin $\hat{2}$ receptor in host defense against <i>Mycobacterium bovis</i> BCG infection. European Journal of Immunology, 1999, 29, 4002-4010.	1.6	40
65	Turning off follicular dendritic cells. Nature, 1998, 395, 26-27.	13.7	186
66	Expression of the lymphotoxin $\hat{2}$ receptor on follicular stromal cells in human lymphoid tissues. Cell Death and Differentiation, 1998, 5, 497-505.	5.0	100
67	Lymph Node Genesis Is Induced by Signaling through the Lymphotoxin $\hat{2}$ Receptor. Immunity, 1998, 9, 71-79.	6.6	266
68	Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology, 1998, 115, 1464-1475.	0.6	145
69	The Sequential Role of Lymphotoxin and B Cells in the Development of Splenic Follicles. Journal of Experimental Medicine, 1998, 187, 997-1007.	4.2	221
70	TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis. Journal of Biological Chemistry, 1997, 272, 32401-32410.	1.6	603
71	TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95). Immunity, 1997, 6, 79-88.	6.6	265
72	Distinct Roles in Lymphoid Organogenesis for Lymphotoxins $\hat{1}$ and $\hat{2}$ Revealed in Lymphotoxin $\hat{2}$ -Deficient Mice. Immunity, 1997, 6, 491-500.	6.6	564

#	ARTICLE	IF	CITATIONS
73	Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice. <i>European Journal of Immunology</i> , 1997, 27, 2033-2042.	1.6	180
74	Lymphotoxin \hat{I}^2 Receptor Triggering Induces Activation of the Nuclear Factor \hat{I}^B Transcription Factor in Some Cell Types. <i>Journal of Biological Chemistry</i> , 1996, 271, 24934-24938.	1.6	63
75	Preparation and Characterization of Soluble Recombinant Heterotrimeric Complexes of Human Lymphotoxins and. <i>Journal of Biological Chemistry</i> , 1996, 271, 8618-8626.	1.6	35
76	Monoclonal antibodies to lipocortin-1 as probes for biological function. <i>FEBS Letters</i> , 1990, 261, 247-252.	1.3	53
77	Interferons and rheumatoid arthritis: insight into interferon biology?. <i>Trends in Immunology</i> , 1987, 8, 372-374.	7.5	39
78	Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. <i>Nature</i> , 1986, 320, 77-81.	13.7	684
79	Motions and interactions of phospholipid head groups at the membrane surface. 2. Head groups with hydroxyl groups. <i>Biochemistry</i> , 1981, 20, 7133-7143.	1.2	16
80	Motions and interactions of phospholipid head groups at the membrane surface. 1. Simple alkyl head groups. <i>Biochemistry</i> , 1981, 20, 7123-7133.	1.2	33
81	Motions and interactions of phospholipid head groups at the membrane surface. 3. Dynamic properties of amine-containing head groups. <i>Biochemistry</i> , 1981, 20, 7144-7151.	1.2	48
82	Bilayers of phosphatidylserine: a deuterium and phosphorus nuclear magnetic resonance study. <i>Biochemistry</i> , 1980, 19, 1262-1270.	1.2	161
83	Ca ²⁺ influx across the excitable membrane of behavioural mutants of <i>Paramecium</i> . <i>Nature</i> , 1976, 259, 491-494.	13.7	35
84	Title is missing!. , 0, 1, .		0